Verastem Oncology (VSTM), which transitioned to a commercial-stage company in 2025 with the launch of Avmapki Fakzynja Co-Pack, is optimistic about driving sustainable growth this year.
Avmapki Fakzynja Co-Pack is a kinase inhibitor combination of avutometinib and defactinib, approved for the treatment of KRAS-mutated recurrent low-grade serous ovarian cancer. It was granted accelerated approval by the FDA in May 2025 and is the first-ever FDA-approved treatment for this indication.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.